PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml

Junyong Fang, E. Metter, Patricia Landis, H. Ballentine Carter

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Objectives. To evaluate the use of prostate-specific antigen (PSA) velocity (PSAV) in assessing prostate cancer risk among men with PSA levels less than 4.0 ng/mL. Methods. The relative risk of, and cumulative probability of freedom from, prostate cancer by PSAV was evaluated in 89 male participants (21 with cancer and 68 controls) of a longitudinal aging study - the Baltimore Longitudinal Study of Aging (National Institute on Aging) - who had serial PSA levels between 2.0 and 4.0 ng/mL for at least 18 months. The relative risk was estimated from a Cox proportional hazards regression model, and the disease-free probability was determined by Kaplan-Meier survival analysis. The sensitivity and specificity of PSAV were calculated as a measure of test validity. Results. The sensitivity and specificity of a PSAV of 0.1 ng/mL per year was 81% and 50%, respectively. The relative risk of prostate cancer was 6.53 (range 1.90 to 22.51) when the PSAV was 0.1 ng/mL per year or more compared with a PSAV of less than 0.1 ng/mL per year (P = 0.0029). At 10 years, the cumulative probability of freedom from prostate cancer was 97.1% (range 91.4% to 100%) and 35.2% (range 14.0% to 56.4%) when the PSAV was less than and greater than 0.1 ng/mL per year, respectively. Survival curves began to differ at less than 5 years after the baseline PSAV determination. Conclusions. The association between PSAV and the subsequent risk of prostate cancer suggests that the PSAV may be useful in the risk assessment of men with lower PSA levels.

Original languageEnglish (US)
Pages (from-to)889-893
Number of pages5
JournalUrology
Volume59
Issue number6
DOIs
StatePublished - May 27 2002
Externally publishedYes

Fingerprint

Prostate-Specific Antigen
Prostatic Neoplasms
Longitudinal Studies
National Institute on Aging (U.S.)
Sensitivity and Specificity
Baltimore
Kaplan-Meier Estimate
Survival Analysis
Proportional Hazards Models
Survival
Neoplasms

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml. / Fang, Junyong; Metter, E.; Landis, Patricia; Carter, H. Ballentine.

In: Urology, Vol. 59, No. 6, 27.05.2002, p. 889-893.

Research output: Contribution to journalArticle

Fang, Junyong ; Metter, E. ; Landis, Patricia ; Carter, H. Ballentine. / PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml. In: Urology. 2002 ; Vol. 59, No. 6. pp. 889-893.
@article{03df20ed2c444e8ebc836c5bcb7a1419,
title = "PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml",
abstract = "Objectives. To evaluate the use of prostate-specific antigen (PSA) velocity (PSAV) in assessing prostate cancer risk among men with PSA levels less than 4.0 ng/mL. Methods. The relative risk of, and cumulative probability of freedom from, prostate cancer by PSAV was evaluated in 89 male participants (21 with cancer and 68 controls) of a longitudinal aging study - the Baltimore Longitudinal Study of Aging (National Institute on Aging) - who had serial PSA levels between 2.0 and 4.0 ng/mL for at least 18 months. The relative risk was estimated from a Cox proportional hazards regression model, and the disease-free probability was determined by Kaplan-Meier survival analysis. The sensitivity and specificity of PSAV were calculated as a measure of test validity. Results. The sensitivity and specificity of a PSAV of 0.1 ng/mL per year was 81{\%} and 50{\%}, respectively. The relative risk of prostate cancer was 6.53 (range 1.90 to 22.51) when the PSAV was 0.1 ng/mL per year or more compared with a PSAV of less than 0.1 ng/mL per year (P = 0.0029). At 10 years, the cumulative probability of freedom from prostate cancer was 97.1{\%} (range 91.4{\%} to 100{\%}) and 35.2{\%} (range 14.0{\%} to 56.4{\%}) when the PSAV was less than and greater than 0.1 ng/mL per year, respectively. Survival curves began to differ at less than 5 years after the baseline PSAV determination. Conclusions. The association between PSAV and the subsequent risk of prostate cancer suggests that the PSAV may be useful in the risk assessment of men with lower PSA levels.",
author = "Junyong Fang and E. Metter and Patricia Landis and Carter, {H. Ballentine}",
year = "2002",
month = "5",
day = "27",
doi = "10.1016/S0090-4295(02)01646-1",
language = "English (US)",
volume = "59",
pages = "889--893",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml

AU - Fang, Junyong

AU - Metter, E.

AU - Landis, Patricia

AU - Carter, H. Ballentine

PY - 2002/5/27

Y1 - 2002/5/27

N2 - Objectives. To evaluate the use of prostate-specific antigen (PSA) velocity (PSAV) in assessing prostate cancer risk among men with PSA levels less than 4.0 ng/mL. Methods. The relative risk of, and cumulative probability of freedom from, prostate cancer by PSAV was evaluated in 89 male participants (21 with cancer and 68 controls) of a longitudinal aging study - the Baltimore Longitudinal Study of Aging (National Institute on Aging) - who had serial PSA levels between 2.0 and 4.0 ng/mL for at least 18 months. The relative risk was estimated from a Cox proportional hazards regression model, and the disease-free probability was determined by Kaplan-Meier survival analysis. The sensitivity and specificity of PSAV were calculated as a measure of test validity. Results. The sensitivity and specificity of a PSAV of 0.1 ng/mL per year was 81% and 50%, respectively. The relative risk of prostate cancer was 6.53 (range 1.90 to 22.51) when the PSAV was 0.1 ng/mL per year or more compared with a PSAV of less than 0.1 ng/mL per year (P = 0.0029). At 10 years, the cumulative probability of freedom from prostate cancer was 97.1% (range 91.4% to 100%) and 35.2% (range 14.0% to 56.4%) when the PSAV was less than and greater than 0.1 ng/mL per year, respectively. Survival curves began to differ at less than 5 years after the baseline PSAV determination. Conclusions. The association between PSAV and the subsequent risk of prostate cancer suggests that the PSAV may be useful in the risk assessment of men with lower PSA levels.

AB - Objectives. To evaluate the use of prostate-specific antigen (PSA) velocity (PSAV) in assessing prostate cancer risk among men with PSA levels less than 4.0 ng/mL. Methods. The relative risk of, and cumulative probability of freedom from, prostate cancer by PSAV was evaluated in 89 male participants (21 with cancer and 68 controls) of a longitudinal aging study - the Baltimore Longitudinal Study of Aging (National Institute on Aging) - who had serial PSA levels between 2.0 and 4.0 ng/mL for at least 18 months. The relative risk was estimated from a Cox proportional hazards regression model, and the disease-free probability was determined by Kaplan-Meier survival analysis. The sensitivity and specificity of PSAV were calculated as a measure of test validity. Results. The sensitivity and specificity of a PSAV of 0.1 ng/mL per year was 81% and 50%, respectively. The relative risk of prostate cancer was 6.53 (range 1.90 to 22.51) when the PSAV was 0.1 ng/mL per year or more compared with a PSAV of less than 0.1 ng/mL per year (P = 0.0029). At 10 years, the cumulative probability of freedom from prostate cancer was 97.1% (range 91.4% to 100%) and 35.2% (range 14.0% to 56.4%) when the PSAV was less than and greater than 0.1 ng/mL per year, respectively. Survival curves began to differ at less than 5 years after the baseline PSAV determination. Conclusions. The association between PSAV and the subsequent risk of prostate cancer suggests that the PSAV may be useful in the risk assessment of men with lower PSA levels.

UR - http://www.scopus.com/inward/record.url?scp=0036097051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036097051&partnerID=8YFLogxK

U2 - 10.1016/S0090-4295(02)01646-1

DO - 10.1016/S0090-4295(02)01646-1

M3 - Article

VL - 59

SP - 889

EP - 893

JO - Urology

JF - Urology

SN - 0090-4295

IS - 6

ER -